TBL1-TBLR1 and Beta-catenin Recruit Each Other to Wnt Target-gene Promoter for Transcription Activation and Oncogenesis
Overview
Authors
Affiliations
Aberrant Wnt signalling promotes oncogenesis by increasing the nuclear accumulation of beta-catenin to activate downstream target genes. However, the mechanism of beta-catenin recruitment to the Wnt target-gene promoter, a critical step for removing the co-repressor complex, is largely unknown. Here, we report that transducin beta-like protein 1 (TBL1) and its highly related family member TBLR1 were required for Wnt-beta-catenin-mediated transcription. Wnt signalling induced the interaction between beta-catenin and TBL1-TBLR1, as well as their binding to Wnt target genes. Importantly, the recruitment of TBL1-TBLR1 and beta-catenin to Wnt target-gene promoters was mutually dependent on each other. Furthermore, the depletion of TBL1-TBLR1 significantly inhibited Wnt-beta-catenin-induced gene expression and oncogenic growth in vitro and in vivo. Our results unravel two new components required for nuclear beta-catenin function, and have important implications in developing new strategies for inhibiting Wnt-beta-catenin-mediated tumorigenesis.
A Putative Frizzled 7-Targeting Compound Acts as a Firefly Luciferase Inhibitor.
Kinsolving J, Gratz L, Voss J, Low B, Shorter E, Jude B J Med Chem. 2024; 67(24):22332-22341.
PMID: 39670643 PMC: 11684006. DOI: 10.1021/acs.jmedchem.4c02766.
PPM1G-mediated TBL1X mRNA splicing promotes cell migration in hepatocellular carcinoma.
Hu L, Shi X, Yuan X, Liu D, Zheng D, Li Y Cancer Sci. 2024; 116(1):67-80.
PMID: 39462759 PMC: 11711060. DOI: 10.1111/cas.16372.
Design, Synthesis, and Biological Evaluation of Selective TBL1X Degraders.
Yang R, Pray B, Alinari L, Li P, Cheng X ACS Med Chem Lett. 2024; 15(10):1699-1707.
PMID: 39411529 PMC: 11472461. DOI: 10.1021/acsmedchemlett.4c00255.
Targeted therapies in hepatocellular carcinoma: past, present, and future.
Gujarathi R, Franses J, Pillai A, Liao C Front Oncol. 2024; 14:1432423.
PMID: 39267840 PMC: 11390354. DOI: 10.3389/fonc.2024.1432423.
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?.
de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prevostel C Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065798 PMC: 11279613. DOI: 10.3390/ph17070949.